From Sweet to Functional: How Magnum’s Health‑Centric Reboot Shapes the Ice‑Cream Market

Watching a 5‑metre Viennetta assemble at Magnum’s flagship plant reveals the pressing question of whether indulgent treats can survive the wellness wave.

Disruptive Trend: The Rise of Healthy Sweets

■1 in 8 Americans use GLP‑1 based weight‑loss drugs.

■In the UK, 1.6 million adults tried weight‑loss medication between 2024‑2025.

■1 in 40 Brits now suffer from gout, linked to increased protein intake.

■The global ice‑cream industry is worth £85 bn, with Magnum holding a critical 20 % market share.

Innovative Product Line: Protein, Vitamin, and Glow

Magnum’s “Hydro:Ice” and “Bonbon” test the limits of functional ice‑cream:

■Hydro:Ice is enriched with C, magnesium, B2 and other nutrients, marketed with neon‑glowing visuals.

■Bonbon offers a “controlled bite” concept, aimed at consumers who monitor portion sizes.

Investor Concerns: Short‑Term Skepticism

■Despite a recent quarterly sales uptick, Jefferies analyst David Hayes warns that ozempic and GLP‑1 impacts may erode future demand.

■Magnum’s stock is the most shorted large‑cap in Europe, reflecting volatility amid these doubts.

Evolution of Consumer Behavior

■The “label‑reading” generation prioritizes ingredient transparency.

■“Functional” ice‑cream merges calorie, protein, and supplement content, embodying a “food‑as‑medicine” mindset.

From Past to Future: The Ice‑Cream Industry’s Transformation

■From the first Acton factory in 1922 to the 1980s golden age, the sector has always adapted to trends.

■The 1990s low‑fat strategy now gives way to protein‑rich, vitamin‑infused offerings.

Markets see this as a signal of a broader shift in consumption patterns driven by health‑centric preferences. Magnum’s agile product portfolio can mitigate short‑term sales volatility while positioning the brand for long‑term value creation. Investors should view this pivot not as a risk but as a strategic growth lever, especially as GLP‑1 usage expands globally.